{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Digestive+Disease&page=15",
    "query": {
      "condition": "Digestive Disease",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 14938,
    "total_pages": 1494,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Digestive+Disease&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Digestive+Disease&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T16:20:35.675Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02925520",
      "title": "Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Parenteral Nutrition-Associated Liver Disease"
      ],
      "interventions": [
        {
          "name": "Omegaven",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cook Children's Health Care System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 5 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02925520"
    },
    {
      "nct_id": "NCT01089959",
      "title": "Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease"
      ],
      "interventions": [
        {
          "name": "esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern Arizona VA Health Care System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-03",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2010-08-19",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01089959"
    },
    {
      "nct_id": "NCT02834780",
      "title": "Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma",
        "Hepatocellular Carcinoma",
        "Liver Cancer",
        "Liver Neoplasms",
        "Hepatic Cancer",
        "Hepatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "H3B-6527",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H3 Biomedicine Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2016-12-28",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Newport Beach, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834780"
    },
    {
      "nct_id": "NCT02273362",
      "title": "Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cirrhosis",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2014-11-24",
      "completion_date": "2022-03-10",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 6,
      "location_summary": "Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02273362"
    },
    {
      "nct_id": "NCT00488774",
      "title": "An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Golimumab 1 mg per kg",
          "type": "DRUG"
        },
        {
          "name": "Golimumab 2 mg per kg",
          "type": "DRUG"
        },
        {
          "name": "Golimumab 4 mg per kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 291,
      "start_date": "2007-08",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2013-06-14",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 36,
      "location_summary": "Orange, California • Roseville, California • Littleton, Colorado + 33 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Bristol",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00488774"
    },
    {
      "nct_id": "NCT04547881",
      "title": "Gravity Assisted Technique for Esophageal Endoscopic Submucosal Dissection (ESD)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Esophageal Neoplasms"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 32,
      "start_date": "2016-12-12",
      "completion_date": "2022-02-04",
      "has_results": false,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04547881"
    },
    {
      "nct_id": "NCT02568267",
      "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cholangiocarcinoma",
        "Colorectal Cancer",
        "Head and Neck Neoplasms",
        "Lymphoma, Large-Cell, Anaplastic",
        "Melanoma",
        "Neuroendocrine Tumors",
        "Non-Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Papillary Thyroid Cancer",
        "Primary Brain Tumors",
        "Renal Cell Carcinoma",
        "Sarcomas",
        "Salivary Gland Cancers",
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Entrectinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 534,
      "start_date": "2015-11-19",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02568267"
    },
    {
      "nct_id": "NCT00003411",
      "title": "Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "motexafin gadolinium",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "1998-11",
      "completion_date": "2002-06",
      "has_results": false,
      "last_update_posted_date": "2016-01-18",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 3,
      "location_summary": "Lebanon, New Hampshire • Pittsburgh, Pennsylvania • Madison, Wisconsin",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003411"
    },
    {
      "nct_id": "NCT00797732",
      "title": "A Pilot Study of Acupuncture Treatment for Dysphagia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Carcinomas, Squamous Cell",
        "Dysphagia"
      ],
      "interventions": [
        {
          "name": "Acupuncture",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2008-12",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-02-13",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00797732"
    },
    {
      "nct_id": "NCT00101998",
      "title": "Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Constipation",
        "Bowel Dysfunction"
      ],
      "interventions": [
        {
          "name": "alvimopan",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2003-10-01",
      "completion_date": "2006-05-01",
      "has_results": false,
      "last_update_posted_date": "2017-08-30",
      "last_synced_at": "2026-10-22T16:20:35.675Z",
      "location_count": 69,
      "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 58 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101998"
    }
  ]
}